BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder (BIMET)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00584961|
Recruitment Status : Completed
First Posted : January 2, 2008
Last Update Posted : February 10, 2010
To assess the prevalence of Metabolic Syndrome in Spanish population with Bipolar I or II Disorder.
To analyse the clinical progress disease in patients with Bipolar I or II Disorder for 12 months using the assessment of the symptoms disease and the progress of metabolic and cardiovascular risk.
To analyse the health status, quality of life and functioning/disability of patients.
|Condition or disease||Intervention/treatment|
|Bipolar Disorder||Other: non-interventional|
|Study Type :||Observational|
|Actual Enrollment :||553 participants|
|Official Title:||BIMET Study: Evolution of Metabolic and Cardiovascular Risks Factors in Patients With Bipolar Disorder|
|Study Start Date :||May 2007|
|Actual Primary Completion Date :||February 2009|
|Actual Study Completion Date :||February 2009|
Patients with diagnosis of Bipolar Disorder (DSM-IV TR)
- Evolution of Modifiable Metabolic and Cardiovascular Risk Factors (Weight, and serum levels of Glucose, Total Cholesterol, LDL-Cholesterol, HDL-Cholesterol and Triglycerides) [ Time Frame: 12 months ]
- Clinical Evolution of the Disease [ Time Frame: 12 months ]
- Cardiovascular Risk [ Time Frame: 12 months ]
- Current pattern of treatment in Bipolar Disorder [ Time Frame: 12 month ]
- Prevalence of Metabolic Syndrome in Spanish Population with Bipolar Disorder [ Time Frame: 1 day ]
- Patient functional impairment [ Time Frame: 12 months ]
- Patient quality of life [ Time Frame: 12 month ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00584961
|Study Director:||Pfizer CT.gov Call Center||Pfizer|